Page 34 - Solid Tumors News Today : Breaking News, Live Updates & Top Stories | Vimarsana

The zeal for antibody-drug conjugates (ADCs), a prominent focus for dealmaking in 2023, shows no signs of waning, as Johnson & Johnson greeted attendees of the J.P. Morgan Healthcare Conference (JPM) with news of its $2 billion buyout of Ambrx Biopharma Inc., picking up rights to an ADC platform along with a promising candidate targeting advanced prostate cancer. Under the terms, J&J agreed to acquire all outstanding shares of San Diego-based Ambrx for $28 apiece, marketing a 105% premium to the firm’s Jan. 5 closing price. Unsurprisingly, Ambrx’s stock (NASDAQ:AMAM) gained 101.5% ...

The consolidation of other immunotherapies and the rise of messenger RNA platforms have boosted scientists’ optimism. However, they point out that there won’t be a universal vaccine for cancer, but rather many highly-personalized ones

Global Phase 3 studies started for bomedemstat , nemtabrutinib , MK-2870 and MK-5684 Comprehensive clinical development programs being initiated for each investigational candidate Demonstrates...

Application based on data from the registrational TRIDENT-1 and CARE trials showing robust responses and durable activity in these patient populations If approved, repotrectinib will offer a...

Pasithea's IND for PAS-004, a novel MEK inhibitor, is FDA-approved for Phase 1 trials in advanced cancer, starting Q1 2024 with early results by Q3....